(Q34084268)

30 July 2017

1 reference

title

Pharmacology of fluorinated pyrimidines: eniluracil (English)

1 reference

ORCID Public Data File 2021

30 July 2017

1 reference

1 reference

author name string

Baker SD

series ordinal

1

1 reference

30 July 2017

publication date

1 November 2000

1 reference

Investigational New Drugs

30 July 2017

published in

1 reference

30 July 2017

volume

18

1 reference

30 July 2017

issue

4

1 reference

30 July 2017

page(s)

373-381

1 reference

https://scigraph.springernature.com/pub.10.1023/a:1006453500629

30 July 2017

exact match

0 references

cites work

5-Ethynyluracil (GW776): effects on the formation of the toxic catabolites of 5-fluorouracil, fluoroacetate and fluorohydroxypropionic acid in the isolated perfused rat liver model

1 reference

12 December 2020

5-Ethynyluracil (776C85): a potent modulator of the pharmacokinetics and antitumor efficacy of 5-fluorouracil

1 reference

12 December 2020

Experimental neurotoxicity of 5-fluorouracil and its derivatives is due to poisoning by the monofluorinated organic metabolites, monofluoroacetic acid and alpha-fluoro-beta-alanine

1 reference

12 December 2020

Clinical pharmacology of 5-fluorouracil

1 reference

12 December 2020

A phase II study of continuous infusion 5-fluorouracil and leucovorin with weekly cisplatin in metastatic colorectal carcinoma

1 reference

12 December 2020

Severe fluorouracil toxicity in a patient with dihydropyrimidine dehydrogenase deficiency

1 reference

12 December 2020

Oral chemotherapy: rationale and future directions

1 reference

12 December 2020

Relationship between fluorouracil systemic exposure and tumor response and patient survival

1 reference

12 December 2020

Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer

1 reference

12 December 2020

Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency. A potentially more common pharmacogenetic syndrome

1 reference

12 December 2020

5-FU therapeutic monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancer

1 reference

12 December 2020

High-dose 5-fluorouracil infusional therapy is associated with hyperammonaemia, lactic acidosis and encephalopathy

1 reference

12 December 2020

Phase I study of eniluracil, a dihydropyrimidine dehydrogenase inactivator, and oral 5-fluorouracil with radiation therapy in patients with recurrent or advanced head and neck cancer

1 reference

12 December 2020

In vivo effect of 5-ethynyluracil on 5-fluorouracil metabolism determined by 19F nuclear magnetic resonance spectroscopy

1 reference

12 December 2020

Phase II trial of cisplatin, fluorouracil, and pure folinic acid for locally advanced head and neck cancer: a pharmacokinetic and clinical survey

1 reference

12 December 2020

Familial pyrimidinemia and pyrimidinuria associated with severe fluorouracil toxicity

1 reference

12 December 2020

Mechanism-based inactivation of dihydropyrimidine dehydrogenase by 5-ethynyluracil

1 reference

12 December 2020

Eniluracil treatment completely inactivates dihydropyrimidine dehydrogenase in colorectal tumors

1 reference

12 December 2020

Attenuation of the antitumor activity of 5-fluorouracil by (R)-5-fluoro-5,6-dihydrouracil

1 reference

12 December 2020

Clinical significance of monitoring serum levels of 5-fluorouracil by continuous infusion in patients with advanced colonic cancer

1 reference

12 December 2020

Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile

1 reference

12 December 2020

Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity

1 reference

12 December 2020

Severe neurotoxicity following 5-fluorouracil-based chemotherapy in a patient with dihydropyrimidine dehydrogenase deficiency

1 reference

12 December 2020

Population study of dihydropyrimidine dehydrogenase in cancer patients

1 reference

12 December 2020

Pharmacodynamics of 5-fluorouracil combined with carboplatin in patients with head and neck cancer

1 reference

12 December 2020

Decreased dihydropyrimidine dehydrogenase activity in a population of patients with breast cancer: implication for 5-fluorouracil-based chemotherapy.

1 reference

12 December 2020

5-Ethynyluracil (776C85): modulation of 5-fluorouracil efficacy and therapeutic index in rats bearing advanced colorectal carcinoma.

1 reference

12 December 2020

Response to fluorouracil therapy in cancer patients: the role of tumoral dihydropyrimidine dehydrogenase activity

1 reference

12 December 2020

Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy

1 reference

12 December 2020

Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infus

1 reference

12 December 2020

Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase

1 reference

12 December 2020

Pharmacokinetics and tissue distribution of 2-fluoro-beta-alanine in rats. Potential relevance to toxicity pattern of 5-fluorouracil.

1 reference

12 December 2020

The acute cerebellar syndrome in 5-fluorouracil chemotherapy: a manifestation of fluoroacetate intoxication

1 reference

12 December 2020

Phase I and pharmacologic study of oral fluorouracil on a chronic daily schedule in combination with the dihydropyrimidine dehydrogenase inactivator eniluracil

1 reference

12 December 2020

Pharmacodynamics of fluorouracil-based induction chemotherapy in advanced head and neck cancer

1 reference

12 December 2020

Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients

1 reference

12 December 2020

Dihydropyrimidine dehydrogenase activity in cancer patients

1 reference

12 December 2020

High inter- and intrapatient variation in 5-fluorouracil plasma concentrations during a prolonged drug infusion.

1 reference

12 December 2020

Incidence and significance of multiple primary malignant neoplasms

1 reference

12 December 2020

5-Ethynyluracil (776C85): inactivation of dihydropyrimidine dehydrogenase in vivo

1 reference

12 December 2020

Identifiers

DOI

10.1023/A:1006453500629

1 reference

Dimensions Publication ID

30 July 2017

1050534976

0 references

1 reference